•
Dec 31, 2022

Sight Sciences Q4 2022 Earnings Report

Sight Sciences reported a 40% increase in revenue compared to the prior year period, driven by increased adoption and utilization of its products. The company also reduced operating expenses and improved financial discipline.

Key Takeaways

Sight Sciences reported strong revenue growth in Q4 2022, driven by increased adoption and utilization of its products. The company also focused on improving operating efficiency and maintaining financial discipline, resulting in reduced operating expenses. The company projects revenue for the full year 2023 to range from $89 million to $94 million, which represents growth of approximately 25% to 32% compared to 2022.

Generated fourth quarter 2022 total revenue of $20.5 million, an increase of 40% compared to the prior year period

Reduced fourth quarter 2022 operating expenses by $3.7 million versus the third quarter of 2022

The number of facilities ordering the OMNIĀ® Surgical System (ā€œOMNIā€) increased to 941 in the fourth quarter of 2022 from 913 in the third quarter of 2022

The installed base of TearCareĀ® System (ā€œTearCareā€) facilities grew to 1,042 on December 31, 2022 from 881 on September 30, 2022

Total Revenue
$20.5M
Previous year: $14.7M
+39.9%
EPS
-$0.35
Previous year: -$0.34
+2.9%
Gross Margin
82%
Previous year: 87%
-5.7%
Operating Expenses
$33.9M
Previous year: $27.5M
+23.6%
Gross Profit
$16.9M
Previous year: $12.7M
+32.4%
Cash and Equivalents
$185M
Previous year: $261M
-29.0%
Free Cash Flow
-$15.6M
Previous year: -$10.9M
+43.7%
Total Assets
$213M
Previous year: $280M
-24.0%

Sight Sciences

Sight Sciences

Sight Sciences Revenue by Segment

Forward Guidance

Sight Sciences projects revenue for the full year 2023 to range from $89 million to $94 million, which represents growth of approximately 25% to 32% compared to 2022.

Revenue & Expenses

Visualization of income flow from segment revenue to net income